botulism antitoxin heptavalent (a, b, c, d, e, f, g) - (equine)
Trade name: BAT
Animal productapprovedOrphan Drug FDA
Approved
Mar 22, 2013
BAT or B.A.T. may refer to: — Wikipedia
Clinical trial activity
1 trials · 4 clinical orgs · 2 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2008 (NCT00636519)
Timeline
2010s
- Jun 29, 2011
Orphan Drug Designation
- Mar 22, 2013
Earliest FDA Approval
- Mar 22, 2013
Emergent BioSolutions — NDA Secondary Org
- Mar 25, 2013
Cangene — First NDA Organization
- Mar 25, 2013
Cangene — NDA Organization
Indications
Approved for
Studied for
Mechanism of action
- Botulinum neurotoxin type AANTAGONIST
botA antagonist
Approval history
- approvedMar 22, 2013
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaBAT ↗
Also known as
- bat
- bat
- botulism antitoxin heptavalent (a, b, c, d, e, f, g) - (equine)
- botulism antitoxin heptavalent (equine) types a-g
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00636519 | Phase 1 | Feb 1, 2008 | Cangene, Department of Health and Human Services, Loma Linda University, R. Richard Sloop, M. D. |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Cangene | For profit | 1 | 1 | 1 | 2008 |
| Department of Health and Human Services | Government | 1 | 0 | 1 | 2008 |
| Loma Linda University | Academic/Hospital | 1 | 0 | 1 | 2008 |
| R. Richard Sloop, M. D. | Academic/Hospital | 1 | 0 | 1 | 2008 |
4 organizations
Page 1 / 1
Marketing (2)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Cangene | For profit | NDA | Mar 25, 2013 |
| Emergent BioSolutions | For profit | NDA2 | Mar 22, 2013 |